Lipid X, a
monosaccharide precursor of
lipid A, has been found to prevent death in animals given a lethal dose of
endotoxin, but the mechanism of this protective effect is unknown. We previously reported that
lipid X blocks
endotoxin-induced priming of human neutrophils in a manner consistent with competitive inhibition. To determine the molecular requirements for this antiendotoxin activity, we studied several derivatives of
lipid X using the neutrophil priming assay. Neutrophil priming was quantitated by measuring stimulated
superoxide (O2-) release. The removal of either acyl group from
lipid X or even the simple change of the
amide to an
ester linkage at C2 of the glucosamide ring resulted in a marked loss of antagonism.
Monosaccharide analogues, structurally related to native
lipid A by the presence of acyloxyacyl side chains, demonstrated marked inhibition of
endotoxin-induced priming at low concentrations but an
endotoxin-like, priming effect at high concentrations. The addition of a
phosphate group at position 4 of the
sugar moiety was the only modification studied so far that produced a pure antagonist with increased antiendotoxin activity. Demonstration of these structural requirements for the antiendotoxin activity of
lipid A analogues supports the hypothesis that this effect may be mediated via specific cellular binding sites.
Lipid X derivatives may be useful for studying the interaction of
endotoxin with cells and their antiendotoxin activity may prove beneficial in the treatment of
septicemia.